Skin Cancer & Melanoma

Researchers have reported the first known case of TIL therapy in a patient with well-controlled HIV and metastatic melanoma.

The FDA's CTGTAC voted 10-3 in favor RP1 plus nivolumab's benefit-risk profile in anti–PD-1–resistant advanced melanoma.

As the FDA's ODAC prepares to weigh in ahead of an August 2, 2026, decision date, take a look at RP1's clinical trial and regulatory journey.

Miguel A. Materin, MD, discussed insights on multidisciplinary care, intra-arterial chemotherapy, and the evolving landscape of uveal melanoma treatments.

Miguel A. Materin, MD, discussed his new leadership role at Northwell Cancer Institute, and why a multidisciplinary approach is critical to managing ocular malignancies.

FDA breakthrough designation and NCCN inclusion elevate Merlin CP-GEP as a tool to refine SLNB decisions in T1b/T2a melanoma, per MERLIN_001 trial data.

In this patient case, a 72-year-old male with primary malignant melanoma of the ascending colon received adjuvant therapy consisting of immunotherapy with PD-1 inhibitors.

The FDA has accepted a BLA resubmission for RP1 plus nivolumab for patients with advanced melanoma.

Binimetinib tablets at 45 mg received tentative FDA approval for patients with melanoma and NSCLC.

A panel of exerts discussed key takeaways happening in the field of cutaneous squamous cell carcinoma.

Sarah Weiss, MD, highlights pivotal updates in uveal melanoma, intratumoral neoadjuvant therapy, and Merkel cell carcinoma from the 2026 ASCO Annual Meeting.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.

Findings from the OptimUM-02 trial may support a new potential therapeutic standard for patients with HLA-A*02:01–negative metastatic uveal melanoma.

Neoadjuvant ipilimumab plus nivolumab and relatlimab achieved a major pathologic response in 73.7% of patients with resectable stage III/IV melanoma.

Data from the KEYNOTE-942 trial confirmed a durable benefit with intismeran plus pembrolizumab among patients with high-risk melanoma.

In 897 patients with advanced melanoma treated with ICI, conditional 5-year PFS rose from 29% at baseline to 91% for those progression-free at 4 years.

An OS of 32.9 months was noted with RP1 plus nivolumab for patients who had progressed on prior anti-PD-1 therapy with advanced melanoma.

Statistical significance was not met with either dose level of fianlimab plus cemiplimab compared with the control arm for patients with advanced melanoma.

iSCIB1+ continues to be studied in the SCOPE trial for patients with advanced melanoma.

Key data from the ATLAS-IT-05 study showed the activity of the oncolytic peptide ruxotemitide plus pembrolizumab in refractory metastatic melanoma.

The 5-year OS rate was 16% and 8% in the tebentafusp and control arms, respectively, for patients with HLA-A*02:01–positive uveal melanoma.

PFS showed statistically significant improvement with darovasertib plus crizotinib in the first line for patients with HLA-A*A2:01–negative metastatic uveal melanoma.

The FDA cited that the data provided for RP1 were insufficient and did not provide substantial evidence of effectiveness for this population.

The SkinJect data set found an overall response rate of approximately 80% for patients with nodular basal cell carcinoma receiving 200 µg of doxorubicin microneedle array.

DecisionDx-Melanoma’s i31-SLNB accurately predicted low nodal positivity and high recurrence-free survival in patients with cutaneous melanoma.